Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2566MR)

This product GTTS-WQ2566MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Ewing sarcoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2566MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13495MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ4031MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ14637MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ5139MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CAN-04
GTTS-WQ2845MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-570
GTTS-WQ7464MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ10799MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M777-16-3
GTTS-WQ9549MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J6M0
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW